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Inflammatory bowel disease is associated with intestinal dysbiosis and with elevated
antibody production toward microbial epitopes. The underlying processes linking the
gut microbiota with inflammation are still unclear. Considering the constant induction
of antibodies by gut microbial glycans, the aim of this study was to address whether
the repertoire of carbohydrate-specific antibodies is altered in Crohn’s disease or
ulcerative colitis. IgG and IgM reactivities to oligosaccharides representative of mucosal
glycans were tested in blood serum from 20 healthy control subjects, 17 ulcerative
colitis patients, and 23 Crohn’s disease patients using glycan arrays. An increased
IgG and IgM reactivity toward fucosylated oligosaccharides was detected in Crohn’s
disease but not in ulcerative colitis. To address the antibody reactivity to the gut
microbiota, IgG binding to members of a complex intestinal microbiota was measured
and observed to be increased in sera of patients with Crohn’s disease. Based on
the elevated reactivity to fucosylated oligosaccharides, gut bacteria were tested for
recognition by the fucose-binding Aleuria aurantia lectin. Bacteroides stercoris was
detected in IgG- and lectin-positive fractions and reactivity of A. aurantia lectin was
demonstrated for additional Bacteroides species. IgG reactivity to these Bacteroides
species was significantly increased in inflammatory bowel disease patients, indicating
that the increased reactivity to fucosylated oligosaccharides detected in Crohn’s disease
may be induced by fucose-carrying intestinal bacteria. Enhanced antibody response to
fucosylated epitopes may have systemic effects by altering the binding of circulating
antibodies to endogenous glycoproteins.
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INTRODUCTION
Inflammatory bowel disease (IBD) encompasses a group of chronic inflammatory diseases of
the gastrointestinal tract including the two major types of ulcerative colitis (UC) and Crohn’s
disease (CD). IBD is a multifactorial disease associated with abnormal mucosal immune responses
combined with altered function of the intestinal barrier and genetic and environmental factors
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(Ramos and Papadakis, 2019). Despite differences between UC
and CD, several features are common to both conditions. UC
mainly affects the mucosal layer of the colon, whereas CD is
characterized by alterations of the whole gastrointestinal bowel
wall (Waugh et al., 2013). Intestinal dysbiosis is frequent in UC
and CD (Nishida et al., 2018). Decreased microbial diversity has
been reported for both diseases, but is often more pronounced
in CD (Ott et al., 2004; Manichanh et al., 2006). Despite
controversial results on the increase or decrease of specific taxa,
studies consistently reported a lower abundance of Firmicutes
in IBD (Manichanh et al., 2006; Frank et al., 2007; Nishida
et al., 2018). Furthermore, IBD is associated with an increase
of potentially inflammatory bacteria, such as adherent-invasive
Escherichia coli (Martin et al., 2004; Nishida et al., 2018), and a
decrease of bacteria with anti-inflammatory characteristics, such
as Faecalibacterium prausnitzii (Fujimoto et al., 2013; Machiels
et al., 2014; Takahashi et al., 2016). A higher abundance of
Bacteroidetes and Proteobacteria, including Enterobacteriaceae
(Seksik et al., 2003; Gophna et al., 2006), has been reported,
even though there are also studies that showed a decrease of
Bacteroidetes (Frank et al., 2007).
IBD is associated with elevated titers of antibodies
targeting microbial epitopes (Mitsuyama et al., 2016).
These antibodies include a panel of carbohydrate-reactive
antibodies, such as anti-laminaribioside, anti-mannobioside,
anti-chitobioside, anti-laminarin and anti-chitin (Dotan
et al., 2006; Rieder et al., 2010; Kaul et al., 2012; Paul
et al., 2015). Exposure to surface glycans of intestinal
bacteria triggers the production of carbohydrate-specific
antibodies (Springer et al., 1961; Springer and Horton,
1969; Macher and Galili, 2008; Yilmaz et al., 2014; Bello-
Gil et al., 2019). Some bacterial and mammalian glycans
share antigenic properties, for example AB0 blood group
antigens, which stimulate the production of AB0-specific
antibodies during the first months of life after microbial
colonization of the gastrointestinal tract (Springer and
Horton, 1969; Dean, 2005). Specific bacteria mimic host
glycan structures to evade recognition by the immune
system (Moran et al., 1996; Comstock and Kasper, 2006).
Antigen mimicry may lead to the formation of cross-
reacting antibodies that recognize structurally related host
glycans. Antibodies against the lipooligosaccharide coat of
Campylobacter jejuni can react with the structurally related
ganglioside GM1 and trigger Guillain-Barré syndrome (Yuki
et al., 2004). In a similar manner, antibodies to bacterial
glycans can recognize similar epitopes expressed on the
intestinal mucosa, thereby possibly contributing to a local
inflammatory response.
Considering the dysbiosis associated with IBD, changes in
the intestinal microbiota may lead to the emergence of novel
antibodies cross-reacting with host intestinal glycans. To address
whether the repertoire of carbohydrate-specific antibodies is
altered in IBD, and whether changes in antibody profiles can be
linked to the expansion of specific bacterial taxa, we investigated
the reactivity of serum antibodies to mucosal glycans in IBD
patients using oligosaccharide arrays.
RESULTS
Increased Serum Antibody Response to
Oligosaccharides in Crohn’s Disease
To analyze the occurrence and diversity of oligosaccharide-
specific antibodies, we determined the reactivity of serum
IgM and IgG to arrays displaying 220 distinct human milk
oligosaccharide structures (Yu et al., 2014). Human milk
oligosaccharides share structural similarities and common
epitopes with mucosal glycans, making them suitable for the
analysis of antibodies to mucosal glycans (Marcobal et al.,
2011; Koropatkin et al., 2012). For these structures only the
composition in terms of the numbers of monosaccharides was
known and abbreviated by the number of hexoses (H), N-acetyl-
hexosamine (N), fucose (F) and N-acetylneuraminic acid as sialic
acid (S) (Supplementary Table S1). We compared 17 sera from
UC and 23 sera from CD patients with 20 sera from healthy
control subjects. Heatmaps of the whole data set showed that
patterns of IgG and IgM reactivity diverged between individual
sera (Supplementary Figure S1), but consistent changes in
subgroups of oligosaccharides were observed. Strikingly high
antibody reactivities in the patients were observed for two groups
of oligosaccharides. Group 1 comprised various undecorated and
fucosylated H4N2 and H5N3 core structures, whereas group
2 consisted of different oligosaccharides with the composition
H3N1F1S1 and H3N1S1 (Figure 1A, Supplementary Figure S1).
In addition, we observed very high reactivities not only in
patients’ samples but also in all control samples for a third
group and two additional structures (Figure 1A, Supplementary
Figure S1). One of the two single oligosaccharides represented
H3N1F1S1 and one structure of group 3 consisted of H5N3F1S1,
whereas the compositions of the other three oligosaccharides
were unknown. Overall, the reactivity of IgG and IgM toward
oligosaccharides was increased in CD sera, whereas IgG and
IgM responses remained unchanged in UC sera (Figure 1B).
The patterns of oligosaccharides recognized by an individual
serum was similar between IgG and IgM (Supplementary
Figure S2). IgG and IgM reactivities correlated significantly
for each serum sample tested. For 39 out of 40 samples the
mean correlation coefficient ranged between 0.67 and 0.98
(Supplementary Table S2). Because of this similarity, we focused
our subsequent analyses on IgG reactivities.
When comparing the IgG reactivity to different
oligosaccharide structures on the array, we analyzed the
IgG binding to oligosaccharides carrying fucose and sialic acid,
which are typical epitopes found on intestinal glycans (Robbe
et al., 2004). IgG response to oligosaccharides containing fucose
or sialic acid was increased in CD sera, whereas recognition
of undecorated oligosaccharides lacking fucose or sialic acid
residues remained unchanged (Figure 2A). The reactivity of
UC sera to different subsets of oligosaccharides also remained
unchanged compared with healthy control sera. Closer analysis
of the subgroups of fucosylated and sialylated oligosaccharides
indicated that the change of IgG reactivity to oligosaccharides
in CD mainly reflected an increased reactivity toward
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FIGURE 1 | Increased serum IgM and IgG reactivity to oligosaccharides in CD patients. (A) Heatmap of the IgG reactivity to oligosaccharide structures for blood
serum from healthy controls (n = 20), UC (n = 17) and CD (n = 23) patients, based on the fluorescence intensities (RFU) measured by glycan array analysis. Shown
are oligosaccharides or groups of oligosaccharides with high IgG reactivities in the CD patients group (group 1, group 2) or in all groups (group 3 and two single
structures, marked with # and ##). The composition of oligosaccharides is indicated by the number of different monosaccharides (hexose, H; HexNAc, N; fucose, F;
sialic acid, S). (B) IgG and IgM reactivities shown as median log (RFU) of all 220 oligosaccharides tested on the glycan array. *p-value ≥ 0.05, determined using
one-way ANOVA and Bonferroni’s post hoc test with selected pairs for ctrl vs UC and ctrl vs CD.
fucosylated but non-sialylated oligosaccharides. The group
of oligosaccharides carrying two to four fucose residues (F2–F4)
showed the largest difference in IgG reactivity between healthy
controls and CD patients (Figure 2B). Again, IgG reactivity
from UC sera toward subtypes of oligosaccharides remained
unchanged. Hierarchical cluster analysis of the same data
confirmed that the majority of control samples did not belong
to the group of samples with high IgG reactivity to fucosylated
oligosaccharides, in which CD samples and UC samples were
frequent (Supplementary Figure S3). The contribution of
fucosylated oligosaccharides to the elevated IgG reactivity to
oligosaccharides was confirmed by calculating the fold change of
IgG reactivity for sample groups (ctrl vs UC, ctrl vs CD) for every
single oligosaccharide. Setting a threshold difference of log-fold
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FIGURE 2 | Serum IgG reactivity to fucosylated oligosaccharides in CD patients. (A) Median IgG reactivities to subgroups of oligosaccharides on the array shown as
log (RFU). (B) Analysis of subgroups of fucosylated and sialylated oligosaccharides (mono-fucosylated, F1; di- to tetra-fucosylated, F2-F4; mono-sialylated, S1;
di-sialylated, S2). (C) Median IgG reactivity to single exemplary fucosylated oligosaccharides and correspondingly undecorated and sialylated oligosaccharides,
shown as RFU. The composition of oligosaccharides is indicated by the number of different monosaccharides (hexose, H; HexNAc, N; fucose, F; sialic acid, S). All
panels include 20 controls, 17 UC and 23 CD samples. * p-value ≥ 0.05, determined using one-way ANOVA and Bonferroni’s post hoc test for panel (A) and (B) or
Kruskal-Wallis test and Dunn’s post hoc test for panel (C), both with selected pairs of ctrl vs UC and ctrl vs CD.
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change (logFC) larger than two, oligosaccharides associated
with increased IgG reactivity mainly belonged to fucosylated
oligosaccharides, whereas all oligosaccharides with decreased
IgG reactivity were sialylated (Table 1).
IgG reactivity to fucosylated oligosaccharides was higher in
CD patients compared with healthy controls. By contrast, IgG
reactivity to undecorated and sialylated oligosaccharides was
similar between IBD patients and healthy controls (Figure 2C).
Interestingly, the presence of sialic acid strongly lowered
antibody reactivity, as shown for H4N2F2S1 in comparison to
related fucosylated and non-sialylated oligosaccharides, such as
H4N2F2 and H4N2F3 (Figure 2C). In general, sialylation was
associated with decreased IgG reactivity to oligosaccharides in
IBD sera (Table 1), even though one specific sialylated and non-
fucosylated oligosaccharide with the composition H3N1S1 was
also among the structures associated with an IgG reactivity in IBD
sera (Table 1).
Increased IgG Reactivity to the Intestinal
Microbiota in CD
Increased IgG response to commensal bacteria in IBD has
been reported not only for mucosal (Macpherson et al.,
1996) but also for systemic antibodies (Adams et al., 2008;
Haas et al., 2011; Harmsen et al., 2012; Castro-Dopico et al.,
2019). Using flow cytometry, we indeed detected increased
TABLE 1 | Oligosaccharides with altered serum IgG reactivity in IBD patients.
Increased IgG reactivity in CD Increased IgG reactivity in UC
Composition logFC P-value Composition logFC P-value
H3N1S1 4.19 0.01 H4N2F3 4.40 0.00
H4N2F3 4.02 0.00 H3N1F1S1 3.70 0.02
H6N4F4/H7N5F2 3.75 0.00 H3N1F1 (LNnFP V) 3.33 0.02
H5N3F3 3.67 0.00 H5N3F2 3.22 0.01
H4N2F2 3.67 0.02 H4N2F2 3.22 0.05
H4N2F3 3.49 0.01 H6N4F3 3.10 0.04
H4N2F2S1 3.44 0.01 H5N3F2 2.92 0.03

















H2F1 (3-FL) 2.14 0.05
H4N2F2S1 2.10 0.03
Decreased IgG reactivity in CD Decreased IgG reactivity in UC
Composition logFC P-value Composition logFC P-value
H5N3F3S1/H6N4F2S1 2.66 0.02 H5N3F1S1 3.91 0.00
H5N3F1S1 2.54 0.03 H5N3F1S1 3.07 0.01
H3N1S1 (LSTb) 2.51 0.03 H5N3F2S1 3.05 0.01
H6N4S1 2.11 0.02 H5N3F2S2 2.83 0.03
H5N3F1S1 2.03 0.04 H6N4S1 2.72 0.01
H6N4F1S1 2.46 0.00
H, hexose; N, N-acetyl-hexosamine; F, fucose; S, sialic acid; 3-FL, 3-Fucosyllactose; LNFP V, Lacto-N-fucopentaose V; LNnFP V, Lacto-N-neofucopentaose V; LNnT,
Lacto-N-neotetraose; LST b, Sialyllacto-N-tetraose b.
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FIGURE 3 | Increased IgG reactivity and decreased IgG repertoire to commensal bacteria in the blood serum of CD patients. (A) Percentage of IgG-positive cells of
an intestinal complex microbiota, determined by flow cytometry, as the result of three independent experiments (different batches of bacterial culture and different
serum samples, n = 20 for ctrl, n = 17 for UC, n = 21 for CD). (B) Alpha-diversity, shown as the number of different OTUs within one sample, grouped by control, UC
and CD, resulting from sorting and 16S sequencing of IgG-bound bacteria of 6 samples per group. *p-value ≥ 0.05, determined using one-way ANOVA and
Bonferroni’s post hoc test with selected pairs for ctrl vs UC and ctrl vs CD.
FIGURE 4 | Bacteroides recognition by serum IgG and by the fucose-binding lectin AAL. (A) AAL-bound bacteria from a healthy human microbiota culture (red)
compared with unstained bacteria from the same microbiota sample (black). (B) All OTUs identified as Bacteroides by 16S sequencing of AAL-bound bacteria as
percentage of total bacteria. (C) Real-time PCR using specific primers for Bacteroides, shown as median ± standard deviation for AAL-bound (AAL+) (n = 3) and
unsorted bacteria (uns. bac.) (n = 3) and for IgG-bound (IgG+) (n = 36) and corresponding unsorted bacteria (uns. bac.) (n = 4). (D) Real-time PCR using specific
primers for B. stercoris, shown as median ± standard deviation for AAL-bound (AAL+) (n = 3) and unsorted bacteria (uns. bac.) (n = 3) and for IgG-bound (IgG+)
(n = 36) and corresponding unsorted bacteria (uns. bac.) (n = 4). *p-value ≥ 0.05, determined by student’s t-test.
IgG binding to bacteria from a healthy intestinal microbiota
in sera from CD patients compared with healthy controls
(Figure 3A). The bacteria bound by serum IgG were isolated
and identified by 16S rRNA sequencing for representative six
healthy controls, six CD and six UC patients (samples are
marked in Supplementary Figure S1). This analysis revealed
a decreased alpha-diversity in the CD group but not in UC
(Figure 3B), indicating a restricted serum IgG repertoire toward
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bacterial antigens in CD. Because of the increased reactivity of
IgG to fucosylated oligosaccharides observed in CD sera, we
analyzed the composition of the bacteria in the healthy human
intestinal microbiota that are recognized by the fucose-binding
Aleuria aurantia lectin (AAL) (Romano et al., 2011). A fraction
representing 20% of the complex bacterial mixture was positive
for AAL binding (Figure 4A). The AAL-positive fraction was
isolated by cell sorting and bacteria were identified by 16S rRNA
sequencing. At the genus level, taxa enriched at least 1.5-fold
included Peptinophilus, Paenibacillus, Agathobacter, Anaerostipes,
Escherichia, Enterococcus, Eubacterium, Holdemania, Slackia,
Proteus, Ruminococcus, Parabacteroides, Ruthenibacterium,
Lachnospira, Bacteroides, Murdochiella, Succiniclaticum,
Frisingicoccus, and Bifidobacterium. In addition, several
unknown genera belonging to the families of Lachnospiraceae,
Ruminococcaceae, and Muribaculaceae were also identified
(Supplementary Figure S4). The comparison of the bacterial
taxa positive for AAL binding and those recognized by IgG
from CD sera pointed to specific taxonomical groups and
single species found in both fractions. Among the taxa enriched
more than 1.5-fold in both AAL-positive and IgG-positive
fractions, we focused on bacteria preferentially enriched after
capture with IgG from CD sera against IgG from healthy
control sera. At the genus level, nine taxa, including Bacteroides,
Slackia, Agathobacter, Enterococcus, Escherichia, Peptoniphilus,
Frisingicoccus, and two unknown taxa, met this criterion.
Bacteroides was the only taxa that included more than a single
species (Figure 4B). Enrichment of Bacteroides in the AAL-
positive and IgG-positive fractions of CD sera was confirmed by
real-time PCR (Figure 4C). Bacteroides stercoris was the major
species representing Bacteroides enrichment in the AAL-positive
and IgG-positive samples (Figure 4D). Notably, an increased
abundance of B. stercoris in fecal samples of CD patients has been
previously reported (Walters et al., 2014).
Bacteroides Fucosylation and
Recognition by IgG in CD Patients
Bacteroidetes is a major phylum of the human intestinal
microbiota and several Bacteroides species have been found
to be enriched in IBD (Swidsinski et al., 2005; Gevers et al.,
2014). The abundance of surface fucosylation on intestinal
Bacteroides species was assessed by analyzing AAL binding
to bacteria using flow cytometry. Fucosylation was confirmed
for B. stercoris and further demonstrated for all additional
Bacteroides species tested, namely B. vulgatus, B. intestinalis, B.
acidifaciens, and B. thetaiotaomicron (Figure 5A). As expected,
E. coli K12 that lacks fucosylated epitopes and was included as
a negative control remained negative for AAL binding (Kramer
et al., 2002; Raetz and Whitfield, 2002). The main glycans
exposed on the cell wall of gram-negative bacteria consist
of the oligosaccharide core of lipopolysaccharides (LPS) and
capsular polysaccharides, which both induce strong antibody
responses (Comstock and Kasper, 2006). To determine the
nature of fucosylated oligosaccharides on Bacteroides surfaces,
we examined AAL reactivity for bacterial proteins and for LPS.
Lectin blots confirmed the presence of fucosylated glycoproteins
on B. thetaiotaomicron, B. vulgatus, B. intestinalis, B. acidifaciens,
and B. stercoris (Figure 5B). By contrast, AAL only bound to
LPS of B. intestinalis (Figure 5C). The fucosylated LPS from
E. coliO127:B8 (Widmalm and Leontein, 1993) was included as a
positive control to confirm the specificity of AAL toward fucose
(Figure 5C). In contrast, in accordance with flow cytometry data
(Figure 5A), AAL did neither react with lysate nor with non-
fucosylated LPS from E. coli K12 (Figures 5B,C) (Kramer et al.,
2002; Raetz and Whitfield, 2002).
Further, we confirmed the increased reactivity of IgG from
CD patients toward B. stercoris and other Bacteroides species
in the serum of CD patients by flow cytometry (Figure 6A).
Increased reactivity toward B. intestinalis and B. acidifaciens was
also noted for IgG from UC patients. The IgG binding profiles
of individual sera toward B. stercoris and B. vulgatus clearly
showed the inter-individual variability in the recognition of these
bacteria by serum IgG and underlined the strong reactivity of
CD sera against these Bacteroides species (Figure 6B). Overall,
our study demonstrated an increased serum antibody reactivity
to fucosylated oligosaccharides and to fucose-carrying members
of the genus Bacteroides in CD.
DISCUSSION
The investigation of carbohydrate-specific antibodies in
IBD patients revealed an increased antibody response to
oligosaccharides in CD patients, which was mainly reflected
by a higher reactivity to fucosylated oligosaccharides. Previous
studies reported an increased serum IgG reactivity to intestinal
commensal bacteria in CD (Adams et al., 2008; Haas et al., 2011;
Harmsen et al., 2012). Our work indicates that this increased
reactivity to bacteria also leads to changes in the specificity of
serum IgG and IgM to oligosaccharide structures. The changes
in antibody specificity are likely the result of the intestinal
dysbiosis that prevails in UC and CD (Nishida et al., 2018). In
addition, we observed a decreased diversity in the repertoire
of anti-bacterial IgG in CD patients compared with healthy
controls and UC patients. The lower diversity of anti-bacterial
IgG likely reflects the decreased microbial diversity reported
in CD patients (Andoh et al., 2012; Quince et al., 2015; Gong
et al., 2016). We observed an increased reactivity of antibodies
to fucosylated oligosaccharides and commensal bacteria in
the sera of CD patients, but not of UC patients. A reason for
the stronger response recorded in CD may be related to the
increased intestinal permeability that mainly occurs in CD
patients, which induces stronger antibody response to intestinal
microbes (Oriishi et al., 1995; Gerova et al., 2011). Interestingly,
intestinal dysbiosis is known for UC and CD patients, but the
changes in microbial composition (Machiels et al., 2014; Pascal
et al., 2017) and the way how the host immune system respond
to dysbiosis appear to differentially influence the emergence of
carbohydrate-specific antibodies.
Increased serum IgG reactivity to fucosylated oligosaccharides
possibly reflects an increase of intestinal microbes expressing
fucosylated surface glycans. Our study showed that several
Bacteroides species carry fucosylated surface glycans and may
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FIGURE 5 | Bacteroides surface glycans recognized by fucose-specific lectin AAL. (A) Flow cytometry histograms of Bacteroides species and E. coli K12 stained
with fluorescein-AAL (red) compared with unstained bacteria (black). (B) Analysis of bacterial cell lysates by SDS-PAGE and Coomassie (loading control) and by
lectin blotting (AAL). The specificity of the AAL signal was confirmed using competing soluble L-fucose (AAL + Fucose). (C) Analysis of isolated LPS by SDS-PAGE
and silver stain (loading control) and by lectin blotting (AAL). The specificity of AAL was tested with the inhibiting sugar L-fucose (AAL + Fucose). Ctrl, E. coli
O127:B8; 1, E. coli K12; 2, B. intestinalis; 3, B. thetaiotaomicron; 4, B. vulgatus; 5, B. stercoris; 6, B. acidifaciens.
contribute to the increased IgG reactivity to fucosylated
oligosaccharides in CD. Typical for gram-negative bacteria,
Bacteroides species express a broad diversity of glycoconjugates
including LPS, capsular polysaccharides and outer membrane
glycoproteins (Poxton and Edmond, 1995; Jacobson et al., 2018),
some of them being fucosylated (Kasper et al., 1983; Meisel-
Mikolajczyk et al., 1989). Several Bacteroides are able to cleave
terminal fucose residues and to internalize and incorporate them
into their own glycans (Hooper et al., 1999; Coyne et al., 2005;
Comstock and Kasper, 2006). Fucosylation of surface glycans also
confers a survival advantage to B. fragilis in the host intestine
(Coyne et al., 2005). While fucose is common on intestinal
bacterial surfaces, the sialic acid N-acetylneuraminic acid is less
frequent and usually associated with pathogens such as E. coli and
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FIGURE 6 | Increased serum IgG reactivity to commensal bacteria of the genus Bacteroides in IBD patients. (A) Mean fluorescence intensity (MFI) of the serum IgG
reactivity to cultured Bacteroides species normalized to the IgG concentration of each serum, determined by flow cytometry (n = 20 for ctrl, n = 17 for UC, n = 21 for
CD). (B) Histograms of 10 samples per group, showing IgG reactivity to indicated Bacteroides species, measured by flow cytometry as indicated in (A).
*p-value ≥ 0.05, determined using one-way ANOVA and Bonferroni’s post hoc test with selected pairs for ctrl vs UC and ctrl vs CD.
C. jejuni (Vimr et al., 2004). Surface sialic acid often increases the
virulence of bacteria by enabling the bacteria to evade immune
recognition, given that sialic acid is a dominant component
of host glycoconjugates that acts as a self-associated molecular
pattern (Varki, 2011). The immune-dampening effect of sialic
acid likely also contributes to the low amount of IgG reacting
against sialylated oligosaccharides in CD sera.
In addition to changes in bacterial fucosylation, mucosal
glycosylation also undergoes remodeling during intestinal
inflammation. Inflammatory cytokines and tissue injury increase
fucosylation in the small intestine as shown by the up-regulation
of the FUT2 fucosyltransferase gene (Umesaki and Ohara, 1989).
Interestingly, intestinal bacteria also enhance fucosylation in the
small intestine. This stimulatory effect appears to be specific
to bacterial taxa, such as segmented filamentous bacteria and
B. thetaiotaomicron (Umesaki et al., 1995; Bry et al., 1996),
whereas others, such as Lactobacilli remain non-stimulatory
(Goto et al., 2014).
This study focused on the specificity of carbohydrate-specific
antibodies and their reactivity toward intestinal bacteria in
IBD. The impact of serum antibodies recognizing fucosylated
oligosaccharides in host tissues has not been addressed. Given the
structural similarities between some bacterial glycans and host
mucosal glycans (Marcobal et al., 2011; Koropatkin et al., 2012),
Frontiers in Microbiology | www.frontiersin.org 9 July 2020 | Volume 11 | Article 1553
Kappler et al. Carbohydrate-Specific Antibodies in Crohn’s Disease
antibodies to bacterial oligosaccharides may cross-react with
host glycoproteins. Elevated levels of specific anti-carbohydrate
antibodies have been linked to IBD and autoimmune diseases,
including Guillain-Barré syndrome, multiple sclerosis, systemic
lupus erythematosus and diabetes type 1 (Gillard et al., 1989;
Schwerer, 2002; Schwarz et al., 2006; Dai et al., 2009).
Investigation of the repertoires of carbohydrate-specific
antibodies in other diseases than IBD may reveal new serum
markers and could help to identify microbial taxa linked to
inflammatory and auto-immune diseases.
MATERIALS AND METHODS
Materials
Anti-human IgG DyLight488 was obtained from Abcam
(Cambridge, MA, United States). Goat anti-human IgG Alexa488
and goat anti-human IgMAlexa647 were purchased from Jackson
ImmunoResearch Laboratories (West Grove, PA, United States).
Biotinylated and fluorescein labeled AAL was bought from
Vector Laboratories (Burlingame, CA, United States). LPS from
E. coli O127:B8 was purchased from Sigma-Aldrich (St. Louis,
MO, United States). Streptavidin-HRP was bought from BD
Pharmingen (Franklin Lakes, NJ, United States). Bacteroides
vulgatus ATCC 8482 (DSM 1447), Bacteroides intestinalis JCM
13265 (DSM 17393), Bacteroides thetaiotaomicron ATCC 29148
(DSM 2079), Bacteroides acidifaciens JCM 10556 (DSM 15896)
and Bacteroides stercoris ATCC 43183 (DSM 19555) were
obtained from the German Collection of Microorganisms and
Cell Cultures (DSMZ, Braunschweig, Germany). E. coli K12
DH5-α was bought from Thermo Fisher Scientific (Waltham,
MA, United States).
Patients and Serum Samples
Blood serum samples from 40 IBD patients were provided
by the Swiss IBD Cohort1. The study of the serum samples
was approved by the Cantonal Ethics Committee of Zurich
(KEK-ZH Nr. 2007-1316). Venous blood samples (10 mL) from
healthy volunteers (without a history of chronic gastrointestinal
or autoimmune diseases) were collected into non-treated BD
vacutainer blood collection tubes (BD Biosciences, Franklin
Lakes, NJ, United States). Clotted blood was centrifuged at
3,000× g for 15min at 4◦C and the supernatant serumwas frozen
at −20◦C. For all serum samples, IgG and IgM concentrations
were determined by ELISA Kits (IgG human ELISA Kit from
Abnova, IgM human ELISA Kit from Abnova (Taipeh, China)
according to the manufacturer’s protocol, using a serum dilution
of 1:2.000.000 for IgG and 1:60.000 for IgM.
Oligosaccharide Arrays
The human milk shotgun glycan microarray (version 223) has
been previously described (Yu et al., 2014) and was provided
by National Center for Functional Glycomics (NCFG), BIDMC,
Harvard University. The composition of glycans on the array is
listed in Supplementary Table S1. Individual slides were loaded
1http://www.ibdcohort.ch/
with 8-well format ProPlate Chambers (Grace Bio-Labs, OR,
United States). After hydrating with TSM-T [20 mM Tris-HCl
pH 7.4, 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2 (TSM)
with 0.05% Tween], arrays were incubated with serum diluted
to 500 µg/mL IgG in binding buffer (TSM-T with 1% BSA) for
1 h at room temperature, washed (4 × TSMT-T, 4 × TSM)
and incubated for 1 h at room temperature with 5 µg/mL
Alexa488-labeled goat anti-human IgG in binding buffer. After
washing as described above, the slides were incubated for 1 h
at room temperature with 5 µg/mL Alexa647 goat anti-human
IgM and washed as described with a final wash of four times
with deionized water. After spin-drying, arrays were scanned at
647and 488 nm using Innoscan 1100 AL (Innopsys, Carbonne,
France). A mask representing the layout of the array was fit
to each image using MAPIX analysis software version 8.5.0
(Innopsys, Carbonne, France). Background fluorescence was
determined as the mean fluorescence signal from areas of a
circle of 330 µm diameter outside the actual spot of 110 µm
diameter. Background signal was subtracted, the mean of four
replicates was calculated and negative values were set to 1. For
further analysis log2 (RFU) was used. Microarray production and
analyses were performed according to the MIRAGE guidelines
(Liu et al., 2017) (Supplementary Data).
Bacterial Cultures
Bacteroides species were cultivated anaerobically in rubber-sealed
hungate tubes at 37◦C in Peptone Yeast Glucosemedium (DSMZ,
medium no. 104 with 1.25 mg/mL glucose). E. coli K 12 was
cultivated aerobically in Luria-Bertani medium at 37◦C. Cells
were harvested at OD = 1.0 in aliquots of 0.5 mL, pelleted by
centrifugation at 13.000 × g for 1 min, washed with phosphate-
buffered saline (PBS) and either stored at−20◦C or fixed with 2%
paraformaldehyde in PBS for 15 min. 10 mL of complex bacterial
cultures from a continuous in vitro intestinal fermentation system
(Poeker et al., 2018) inoculated with fecal microbiota of a healthy
human adult were directly transferred from the fermenter into
a sterile, CO2-flushed hungate tube, which was kept on ice. The
culture was centrifuged at 13,000× g for 1min to receive bacterial
pellets. Bacteria were fixed using 2% paraformaldehyde in PBS for
15 min followed by a washing step with PBS.
Flow Cytometry
Fixed bacteria were treated with 10 µg/mL fluorescein labeled
AAL in PBS or diluted serum (1:100) in PBS for 1 h at room
temperature and washed twice using PBS. Serum-treated bacteria
were further stained with anti-human IgG DyLight488 for 1 h at
room temperature and washed twice with PBS. Fluorescence was
recorded by a FACSCanto II Flow cytometer (BD Biosciences,
Franklin Lakes, NJ, United States). AAL positive and IgG positive
bacteria were sorted using a FACSAria III Cell Sorter (BD
Bioscience, Franklin Lakes, NJ, United States). The analysis was
performed using the FlowJo software (BD Bioscience, Franklin
Lakes, NJ, United States).
16S rRNA Sequencing
Bacterial pellets were treated with Proteinase K (2% V/V of
20mg/mL stock, ThermoScientific,Waltham,MA,United States)
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in lysis buffer (50 mM KCl, 10 mM Tris Base, 0.45% Non-
idet P-40, 0.45% Tween 20) for 45 min at 50◦C. After the
inactivation of Proteinase K at 95◦C for 10 min, the addition of
two volumes of PBS and centrifugation at 13.000 × g for 1 min,
the supernatant, containing DNA, was stored at −20◦C. The
V3,V4 region was amplified by PCR using 1 µL DNA template,
200 nM primers 341Fnex0-3 and 802Rnex0-3 (Table 2), Taq
DNA polymerase from Thermus aquaticus (Sigma-Aldrich, St.
Louis, MO, United States) and 100 µMdNTP (ThermoScientific,
Waltham, MA, United States) with the following conditions:
initial denaturation at 95◦C for 5 min, 30 cycles at 98◦C for 20 s,
56◦C for 15 s, and 72◦C for 15 s, and a final step at 72◦C for
2 min. PCR products were cleaned using magnetic SPRI beads
[self-made by Genetic Diversity Center, ETH Zurich, Switzerland
(DeAngelis et al., 1995)]. In brief, 0.8× SPRI beads were added to
each reaction mix and incubated for 5 min at room temperature.
The supernatant was discarded, beads were washed twice using
80% ethanol and DNA was eluted from air-dried beads in 10 mM
Tris pH 8.5. A second PCR was performed using primers with
Illumina adaptors (Nextera XT Index Kit v2, Illumina, San Diego,
CA, United States) according to the manufacturer’s manual. PCR
products were cleaned using magnetic SPRI beads as described
above. DNA concentration of each sample was determined using
the dsDNA HS Assay Kit (ThermoScientific, Waltham, MA,
United States) according to the manufacturer’s protocol. All
samples were normalized and pooled. Amplicons were sequenced
using a paired-end 600 cycles (PE300) Illumina-MiSeq system
(Illumina, San Diego, CA, United States) and quality controlled
with FastQC (Andrews, 2010) and MultiQC (Ewels et al., 2016).
The raw reads were end-trimmed using USEARCH (Edgar, 2010)
and pairs were merged using FLASH (Magoc and Salzberg, 2011).
Primer sequences were trimmed (Edgar, 2010) and reads were
quality controlled using PRINSEQ (Schmieder and Edwards,
2011). UPARSE and UNOISE3 were used to cluster the data into
OTUs, zero-radius OTUs and obtain count tables (Edgar, 2010).
Taxonomic predictions were assigned using Sintax (Edgar, 2016)
with the EzBioCloud 16S database (Yoon et al., 2017). For each
OTU within each sample, the percentage of total bacteria was
calculated. Fold enrichment of taxa was quantified as proportion
of the corresponding unsorted bacterial sample.
Quantitative PCR
Bacteroides spp. and B. stercoris were quantified as proportion
of total bacterial 16S rRNA amplicons by real-time PCR
using the KAPA SYBR FAST qPCR Master Mix Kit (Kapa
Biosystems, Wilmington, MA, United States). Primer pairs
for total bacteria (515F: 5′-GTGCCAGCMGCCGCGGTAA-3′;
805R: 5′-GACTACCAGGGTATCTAAT-3′) (Frank et al., 2007),
Bacteroides spp. (forward: 5′-AAGGTCCCCCACATTGG-3′;
reverse: 5′-GAGCCGCAAACTTTCACAA-3′) (Manz et al.,
1996; Franks et al., 1998; Hermann-Bank et al., 2013) and
B. stercoris (forward: 5′ GCTTGCTTTGATGGATGGC; reverse:
5′ CATGCGGGAAAACTATGCC) (Tong et al., 2011) were
described previously. PCR conditions were initial denaturation
at 95◦C for 3 min, 50 cycles at 95◦C for 10 s and 60◦C (62◦C)
for 30 s, and a final dissociation curve with a gradient from 60◦C
(62◦C) to 95◦C, where 60◦C was used as annealing temperature
for Bacteroides spp. primers and 62◦C for B. stercoris primers.
Each sample was additionally amplified with primers for total
bacteria on the same 96-well plate. The expression relative to total
bacterial 16S rRNA amplicons was calculated using the 2−1 Ct
method (Schmittgen and Livak, 2008).
Lectin Blots and SDS-PAGE
Bacterial pellets were resuspended in 200 µL SDS buffer (2%
β-mercaptoethanol, 2% SDS, 10% glycerol in 50 mM Tris-HCl,
bromphenol blue, pH 6.8), boiled at 99◦C for 15 min and cell
lysates were stored at −20◦C. LPS was extracted by hot aqueous-
phenol extraction (Davis and Goldberg, 2012) and stored at
−20◦C. For lectin blots, either 7.5µL bacterial cell lysates or 5µL
LPS, diluted 1:1 in 2∗SDS buffer, were run on 14% acrylamide
gels at 80 V for 2 h. Gels with cell lysates were stained with
colloidal Coomassie (Dyballa and Metzger, 2009) and gels with
LPS were stained by silver staining (Blum et al., 1987; Fomsgaard
et al., 1990). In brief, gels were incubated in an oxidation solution
consisting of 40% ethanol, 5% acetic acid, 0.7% periodic acid for
20 min, washed twice in 30% ethanol, 1× deionized water, 20 min
each and incubated in 0.02% sodium thiosulfate for 1 min. Gels
were washed three times with deionized water and stained with
0.1% silver nitrate for 20 min at 4◦C.Washed gels were developed
using 3% sodium carbonate and 0.05% formaldehyde 37% until
clear bands were visible. Development was stopped by 5% acetic
acid for 5 min and gels were scanned (CanoScan 9000F Mark
II scanner, Canon, Tokyo, Japan). For lectin blots, SDS-PAGE
gels were transferred to PVDF membranes at 250 mA for 1 h.
Membranes were blocked ON at 4◦Cwith 1% BSA in PBS-T (PBS
with 0.1% Tween20) and incubated with 10 µg/mL biotinylated
AAL or with 10 µg/mL biotinylated AAL and 200 mM L-fucose
TABLE 2 | Primer for 16S sequencing of V3V4 region.
name Nextera adapter linker shift primer site (5′–3′)
341F_nex0 TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG T CCTACGGGNGGCWGCAG
341F_nex1 TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG NT CCTACGGGNGGCWGCAG
341F_nex2 TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG NNT CCTACGGGNGGCWGCAG
341F_nex3 TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG NNNT CCTACGGGNGGCWGCAG
802R_nex0 GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG T TACNVGGGTATCTAATCC
802R_nex1 GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG NT TACNVGGGTATCTAATCC
802R_nex2 GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG NNT TACNVGGGTATCTAATCC
802R_nex3 GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG NNNT TACNVGGGTATCTAATCC
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in PBS-T for 1 h at room temperature, after a pre-incubation
of AAL and L-fucose for 30 min. Membranes were washed four
times with PBS-T for 10 min, incubated with Streptavidin-HRP
(1:1000) for 1 h at room temperature. After another washing step,
identical to the one described above, membranes were detected
using SuperSignal R© West Pico chemiluminescence substrate
(Thermo Fisher Scientific, Waltham, MA, United States) and a
Fujifilm LAS-4000 luminescence image analyzer (GE Healthcare,
Chicago, IL, United States).
Statistics
Data are shown as median values and standard deviation.
Statistical analysis was performed using GraphPad Prism
(GraphPad software, San Diego, CA, United States). For
comparison of two groups (unsorted bacteria vs IgG+, unsorted
bacteria vs AAL+), a student’s t-test was used. For comparison
of multiple groups (ctrl, UC, CD), one-way ANOVA and
Bonferroni’s post hoc test for Gauss distributed samples or
Kruskal-Wallis test and Dunn’s post hoc test for non-Gauss
distributed samples with selected pairs of ctrl vs CD and ctrl vs
UC were applied as indicated in the Figure legends. Results with
p-value ≤ 0.05 were considered significantly different. Pearson’s
correlation analysis was performed using GraphPad Prism. To
compare the IgG reactivity to single oligosaccharides for patients
and control groupsa software tool run on R (version V3.6.1)
using the “limma” package (Ritchie et al., 2015), fitting a linear
model for each feature and testing differential reactivity, with
a modified t-test was used. Unsupervised hierarchical cluster
analysis is based on amatrix with the correlation coefficients of all
sample pairs. Clustering and visualization were performed using
the “complete-linkage” method in R (version V3.6.1) and the R
package pheatmap.
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